Evidence map›Paper›PMID 38425988›Full record

ArticleTherapeutic advances in medical oncology2024

A remnant never forgotten: the utility of circulating tumor DNA in treatment guidance of urachal cancer.

Christopher Ryan Grant, David J Benjamin, Scott Cramer, Arash Rezazadeh Kalebasty

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Christopher Ryan GrantDepartment of Medicine, University of California Irvine Medical Center, UC Irvine Health, 200 S Manchester Avenue, Room 423, Orange, CA 92868, USA.ORCID https://orcid.org/0009-0001-6432-5635
David J BenjaminHoag Family Cancer Institute, Newport Beach, CA, USA.
Scott CramerDepartment of Radiology, University of California Irvine Medical Center, Orange, CA, USA.
Arash Rezazadeh KalebastyDivision of Hematology/Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA.
University of California, Irvine Medical Center · USHoag Memorial Hospital Presbyterian · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urachal cancer is a rare malignancy of the urachus that is treated with surgical resection if localized and systemic chemotherapy for metastatic disease. Circulating tumor DNA (ctDNA) is a single-stranded or double-stranded DNA released by tumor cells into the blood and harbored the mutations of the original tumor, shedding new light on molecular diagnosis and monitoring of cancer. We report a case of resected localized urachal cancer with clear surgical margins and negative lymph node dissection but elevated ctDNA that progressed to metastatic disease. We also highlight the possibility of using ctDNA levels to assist in adjuvant therapy.

Indexed as

circulating tumor DNAurachal cancerurachal remnanturachus

Identifiers

PMID38425988
PMCPMC10903217
OpenAlexW4392250443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.